Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of br...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 710 0512

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

Muscle24 Jul. 14 at 8:55 PM

$INMB Another bullish news is today’s volume chewed through a good chunk if not all of the remaining exercised 647,000 warrants!!! Those warrants were exercise at $1.40 and barely acted as a magnet to bring the price below $2!! Super bullish

0 · Reply

Muscle24 Jul. 14 at 8:51 PM

$INMB Nice bullish engulfing candle on the 180 days chart. The rest of the week is going to be pretty interesting!

0 · Reply

bioinvestorrr Jul. 14 at 8:33 PM

$INMB great close

0 · Reply

NachoBusiness Jul. 14 at 6:52 PM

$INMB hold $2

0 · Reply

djcal Jul. 14 at 6:07 PM

$INMB Take your foot off the gas --- Yeah that's just what you do with a potential short squeeze. I hate stocks where a majority of stocks are in retails hands. Broke my rule on this one because of the science.

1 · Reply

Detroitvehicle Jul. 14 at 5:20 PM

$INMB Low float squeeze beginning

0 · Reply

Detroitvehicle Jul. 14 at 5:17 PM

$INMB - Squeez - low float - about to explode

0 · Reply

Muscle24 Jul. 14 at 5:12 PM

$INMB Remember this post!!!

0 · Reply

Muscle24 Jul. 14 at 5:11 PM

$INMB Like I had said this is an extremely bullish set-up! Anyone who trades using technical analysis would never short such a set-up.

0 · Reply

Ganjaaroi Jul. 14 at 5:07 PM

$INMB let's break 2.3 and then 4 in an instant. gltal

0 · Reply

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC

2026-07-01T11:20:37.000Z - 13 days ago

INmune Bio advances CORDStrom platform patent application in the U.S.

Jul 1, 2026, 7:00 AM EDT - 13 days ago

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

2026-06-25T11:15:15.000Z - 19 days ago

INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan

Jun 25, 2026, 7:00 AM EDT - 19 days ago

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

2026-06-23T16:47:42.000Z - 21 days ago

INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting

Jun 23, 2026, 8:00 AM EDT - 21 days ago

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

Jun 16, 2026, 10:00 AM EDT - 4 weeks ago

INmune Bio Transcript: AGM 2026

2026-06-02T14:35:32.000Z - 6 weeks ago

INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

Jun 2, 2026, 7:00 AM EDT - 6 weeks ago

INmune Bio Slides: Corporate presentation

2026-05-15T13:24:06.000Z - 2 months ago

INmune Bio publishes MINDFuL trial results in NPJ Dementia

May 15, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

2026-05-14T14:59:02.000Z - 2 months ago

INmune Bio receives fast track designation from FDA for XPro

May 14, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

May 13, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

May 7, 2026, 4:30 PM EDT - 2 months ago

INmune Bio Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

INmune Bio Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

INmune Bio Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update

May 5, 2026, 4:00 PM EDT - 2 months ago

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

Apr 30, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

Apr 23, 2026, 8:00 AM EDT - 2 months ago

INmune Bio Proxy statement: Proxy filing

2026-04-16T14:16:48.000Z - 3 months ago

INmune Bio announces new preclinical data for INB03

Mar 30, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 3 months ago

INmune Bio Earnings release: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 3 months ago

INmune Bio Inc. Announces 2025 Results and Provides Business Update

Mar 24, 2026, 8:00 AM EDT - 4 months ago

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.

2026-03-19T12:37:41.000Z - 4 months ago

INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s

2026-03-11T10:11:18.000Z - 4 months ago

INmune Bio upgraded to Buy from Neutral at Lucid Capital

Mar 10, 2026, 7:00 AM EDT - 4 months ago

INmune Bio Slides: Corporate presentation

Feb 26, 2026, 1:00 PM EST - 4 months ago

INmune Bio Transcript: Study update

Feb 23, 2026, 9:25 AM EST - 5 months ago

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar

Feb 19, 2026, 12:15 PM EST - 5 months ago

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

2026-02-12T12:20:01.000Z - 5 months ago

INmune Bio announces FDA alignment on phase 2b/3 registration pathway

2026-02-10T13:12:07.000Z - 5 months ago

INmune Bio submits pre-submission package for CORDStrom with MHRA

Feb 10, 2026, 8:00 AM EST - 5 months ago

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

2026-01-27T14:30:16.000Z - 6 months ago

INmune Bio CEO says ‘well positioned for continued execution’

Jan 27, 2026, 9:25 AM EST - 6 months ago

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

2025-12-05T12:10:33.000Z - 7 months ago

INmune Bio publishes study on INmune’s CORDStrom platform

Dec 5, 2025, 7:00 AM EST - 7 months ago

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

2025-12-01T13:20:57.000Z - 8 months ago

INmune Bio announces neuroimaging data from Phase 2 MINDFuL trial

Dec 1, 2025, 8:00 AM EST - 8 months ago

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients

Nov 18, 2025, 8:00 AM EST - 8 months ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

2025-10-30T20:46:45.000Z - 9 months ago

INmune Bio reports Q3 EPS (24c), consensus (32c)

Oct 30, 2025, 4:30 PM EDT - 9 months ago

INmune Bio Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

INmune Bio Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

INmune Bio Quarterly report: Q3 2025

Oct 30, 2025, 4:05 PM EDT - 9 months ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Oct 14, 2025, 8:00 AM EDT - 9 months ago

INmune Bio Proxy statement: Proxy Filing

Oct 14, 2025, 7:00 AM EDT - 9 months ago

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Oct 3, 2025, 8:00 AM EDT - 10 months ago

INmune Bio Proxy statement: Proxy Filing

2025-09-29T12:20:16.000Z - 10 months ago

INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia

2025-09-15T12:10:30.000Z - 10 months ago

INmune Bio completes first commercial manufacturing run of CORDStrom

2025-08-07T21:55:30.000Z - 1 year ago

INmune Bio CEO RJ Tesi retires, David Moss succeeds

2025-08-07T21:50:15.000Z - 1 year ago

INmune Bio reports Q2 EPS ($1.05), consensus (38c)

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Slides: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 1 year ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jun 30, 2025, 4:05 PM EDT - 1 year ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Transcript: Status Update

Jun 30, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Press release: Status Update

Jun 30, 2025, 7:36 AM EDT - 1 year ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:30 AM EDT - 1 year ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 27, 2025, 12:16 PM EDT - 1 year ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 26, 2025, 4:00 PM EDT - 1 year ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

May 9, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q1 2025

May 8, 2025, 4:10 PM EDT - 1 year ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Apr 25, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Apr 3, 2025, 7:00 AM EDT - 1 year ago

INmune Bio Slides: Corporate Presentation

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

INmune Bio Annual report: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Feb 12, 2025, 7:00 AM EST - 1 year ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 10, 2025, 8:30 AM EST - 1 year ago

INmune Bio Transcript: Study Result

Feb 10, 2025, 7:00 AM EST - 1 year ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Dec 4, 2024, 9:00 AM EST - 1 year ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

INmune Bio Quarterly report: Q3 2024

Oct 31, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 1 year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 26, 2024, 8:00 AM EDT - 1 year ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 3, 2024, 9:00 AM EDT - 2 years ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Aug 2, 2024, 8:00 AM EDT - 2 years ago

INmune Bio Registration statement: Registration Filing

Aug 1, 2024, 4:30 PM EDT - 2 years ago

INmune Bio Earnings Call Transcript: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 2 years ago

INmune Bio Quarterly report: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 2 years ago

INmune Bio Earnings release: Q2 2024

Aug 1, 2024, 4:05 PM EDT - 2 years ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Jul 29, 2024, 9:00 AM EDT - 2 years ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 25, 2024, 8:00 AM EDT - 2 years ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Jul 23, 2024, 8:45 AM EDT - 2 years ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Muscle24 Jul. 14 at 8:55 PM

0 · Reply

Muscle24 Jul. 14 at 8:51 PM

$INMB Nice bullish engulfing candle on the 180 days chart. The rest of the week is going to be pretty interesting!

0 · Reply

bioinvestorrr Jul. 14 at 8:33 PM

$INMB great close

0 · Reply

NachoBusiness Jul. 14 at 6:52 PM

$INMB hold $2

0 · Reply

djcal Jul. 14 at 6:07 PM

1 · Reply

Detroitvehicle Jul. 14 at 5:20 PM

$INMB Low float squeeze beginning

0 · Reply

Detroitvehicle Jul. 14 at 5:17 PM

$INMB - Squeez - low float - about to explode

0 · Reply

Muscle24 Jul. 14 at 5:12 PM

$INMB Remember this post!!!

0 · Reply

Muscle24 Jul. 14 at 5:11 PM

$INMB Like I had said this is an extremely bullish set-up! Anyone who trades using technical analysis would never short such a set-up.

0 · Reply

Ganjaaroi Jul. 14 at 5:07 PM

$INMB let's break 2.3 and then 4 in an instant. gltal

0 · Reply

Muscle24 Jul. 14 at 4:43 PM

$INMB let’s Squeeze them!!! Past $2.05 on very low volume! Bulls have full control!

0 · Reply

alexx013 Jul. 14 at 4:37 PM

$INMB sold 10% @ 2.05

0 · Reply

Muscle24 Jul. 14 at 4:14 PM

$INMB Imminent short squeeze panic buy if they cannot bring this below $2 by EOD

0 · Reply

bioinvestorrr Jul. 14 at 4:09 PM

$INMB nothing like a fresh start, been here for a while. Glad to see it gaining respect back (and my money back)

0 · Reply

10baggerPete Jul. 14 at 3:48 PM

$INMB very nice run. Well done me.

0 · Reply

alexx013 Jul. 14 at 2:30 PM

$INMB nice

0 · Reply

Muscle24 Jul. 14 at 2:12 PM

$INMB We briefly touched $2.01 this morning with 100k shares traded. The order book is thin! We need pr!!!

1 · Reply

bioinvestorrr Jul. 14 at 2:03 PM

$INMB hi 2$

0 · Reply

Muscle24 Jul. 14 at 2:01 PM

$INMB Lol look it went past $2.00 as soon as I got done typing 🤣🤣🤣🤣

0 · Reply

Tide16 Jul. 14 at 2:00 PM

$INMB

0 · Reply

Muscle24 Jul. 14 at 1:56 PM

$INMB Hopefully we can go past $2 now that the 647,000 warrants should be almost done being flipped. I completely forgot about those warrants which I am sure contributed to the muted consolidation after the AAIC. Let’s hope the 900k raised is enough of a cash runway for their next operational hurdles.

1 · Reply

NachoBusiness Jul. 14 at 1:48 PM

$INMB volume is gone today, hopefully a slow grind up

0 · Reply

Market Cap	49.45M
Revenue (ttm)	50,000.00
Net Income (ttm)	-45.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-91,860.00%
Debt to Equity Ratio	0.00

Volume	1,043,700
Avg Vol	858,560
Day's Range	N/A - N/A
Shares Out	26.59M
Stochastic %K	89%
Beta	0.97
Analysts	Strong Sell
Price Target	$7.00